Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment

References

• Nozaki M, Kashiwase K, Saito I Health spending in Japan: macro-fiscal implications and reform options. IMF working paper WP/14/142. Washington: IMF; 2014.
   Google Scholar
• Ikegami N, Anderson G. In Japan, all-payer rate setting under tight government control has proved to be an effective approach to containing costs. Health Affairs. 2012;31(5):1049–1056.
   Web of Science ®Google Scholar
• Reekie DW. Price and quality competition in the United States drug industry. J Ind Econ. 1978;26:223–237.
   Web of Science ®Google Scholar
• Weston JF. Pricing in the pharmaceutical industry. In: Chien RI, editor. Issues in pharmaceutical economics. Lexington (MA): D.C.Heath; 1979.
   Google Scholar
• Weston JF. A survey of the economics of the pharmaceutical industry with emphasis on economic factors in price differentials. In The effectiveness of medicines in containing dental care costs: impact of innovation, regulation, and quality. Washington (DC): National Pharmaceutical Council; 1982.
   Google Scholar
• Lu ZJ, Comanor WS. Strategic pricing of new pharmaceuticals. Rev Econ Stat. 1998;80:108–118.
   Web of Science ®Google Scholar
• Suslow V. Measuring quality change in pharmaceutical markets: hedonic price indexes for anti-ulcer drugs. In: Helms R, editor. Competitive strategies in the pharmaceutical industry. Washington: American Enterprise Institute; 1996. p. 49–72.
   Google Scholar
• Berndt ER, Bui L, Reiley DR, et al. Information, marketing, and pricing in the U.S. antiulcer drug market. Am Econ Rev. 1999;85(2):100–105.
   Google Scholar
• Cockburn IM, Anis AH. Hedonic analysis of arthritis drugs. In: Cutler DM, Berndt ER, editors. Medical care output. Chicago (IL): University of Chicago Press; 2001. p. 439–458.
   Google Scholar
• Chen J, Rizzo J. Pricing dynamics and product quality: the case of antidepressant drugs. Empir Econ. 2012;42(1):279–300.
   Web of Science ®Google Scholar
• Bond R, Lean D. Sales promotion and product differentiation in two prescription drug markets. Washington: Federal Trade Commission; 1977.
   Google Scholar
• Statman M. The effect of patent expiration on the market positions of drugs. Managerial Decis Econ. 1981;2:61–66.
   Google Scholar
• Grabowski H, Vernon J. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug act. J Law Econ. 1992;35:331–350.
   Web of Science ®Google Scholar
• Grabowski H, Vernon J. Longer patents for increased generic competition: the waxman-hatch act after one decade. Pharmacoeconomics. 1996;10:110–123.
   PubMed Web of Science ®Google Scholar
• Caves R, Whinston M, Hurwitz M. Patent expiration, entry and competition in the U.S. pharmaceutical industry: an exploratory analysis. Brookings papers on Economic activity. Microeconomics. 1991;1–48.
   Google Scholar
• Frank R, Salkever D. Generic entry and the pricing of pharmaceuticals. J Econ Manag Strategy. 1997;6(1):75–90.
   Web of Science ®Google Scholar
• Saha A, Grabowski H, Birnbaum H, et al. Generic competition in the US pharmaceutical industry. Int J Econ Business. 2006;13:15–38.
   Google Scholar
• Danzon PM, Chao LW. Does regulation drive out competition in pharmaceutical markets? J Law Econ. 2000;43:311–357.
   Web of Science ®Google Scholar
• Eklund M, Persson B. Pharmaceutical pricing in a regulated market. Rev Econ Stat. 2003;85:298–306.
   Web of Science ®Google Scholar
• Wang YR. Price competition in the Chinese pharmaceutical market. Int J Health Care Finance Econ. 2006;6:119–129.
   PubMedGoogle Scholar
• Wu J, Xu J, Liu G, et al. Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals. Pharmacoeconomics. 2014;32(3):293–303.
   PubMed Web of Science ®Google Scholar
• Mahlich J, Sruamsiri R. Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents. Curr Med Res Opin. 2017;33(1):101–107.
   PubMed Web of Science ®Google Scholar
• Mahlich J, Roediger-Schluga T. Determinants of Pharmaceutical R&D: Evidence from Japan. Rev Ind Organ. 2006;28(2):145–164.
   Web of Science ®Google Scholar
• Statistics Japan. Report on the Consumer Price Index. Tokyo; 2015. Available from: http://www.stat.go.jp/english/data/cpi/1588.htm
   Google Scholar
• Pincus T. The American College of Rheumatology (ACR) core data set and derivative “patient only” indices to assess rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(Suppl. 39):109–113.
   Google Scholar
• Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. Plos One. 2012;7(1):e30275.
   PubMed Web of Science ®Google Scholar
• Orme M, Macgilchrist KS, Mitchell S, et al. Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. Biologics. 2012;6:429–464.
   PubMedGoogle Scholar
• Agency for Healthcare Research and Quality. Comparative effectiveness of drug therapy for rheumatoid arthritis and psoriatic arthritis in adults. Comp Effectiveness Rev. 2010;11.
   Google Scholar
• Nguyen M, Kabir M, Ravaud P. Short-term efficacy and safety of leflunomide in the treatment of active rheumatoid arthritis in everyday clinical use: open-label, prospective study. Clin Drug Investig. 2004;24(2):103–112.
   PubMed Web of Science ®Google Scholar
• Mahlich J. The Japanese pharmaceutical industry in transition: has higher research orientation resulted in higher market value? Asian Bus Manage. 2007;6(1):75–94.
   Web of Science ®Google Scholar
• Kawai N, Kob J-H. The dark sides of institutionalized informal connections: evidence from the Japanese banking sector in the post-bubble crisis era. Int J Business. 2012;7(3):238–257.
   Google Scholar
• OECD. Gross domestic product. Paris; 2016 Available from: https://stats.oecd.org/index.aspx?queryid=60702
   Google Scholar
• Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2011;15(10):i-xxi, 1-329.
   Web of Science ®Google Scholar
• Mahlich J, Kamae I, Rossi B. A new health technology assessment system for Japan? simulating the potential impact on the price of simeprevir. Int J Technol Assess Health Care. 2017;33(1):121–127.
   PubMed Web of Science ®Google Scholar
• Thokala P, Duenas A. Multiple criteria decision analysis for health technology assessment. Value Health. 2012;15(8):1172–1181.
   PubMed Web of Science ®Google Scholar
• Angelis A, Kanavos P. Value-based assessment of new medical technologies: towards a robust methodological framework for the application of multiple criteria decision analysis in the context of health technology assessment. PharmacoEconomics. 2016;34:435–446.
   PubMed Web of Science ®Google Scholar
• Goldman D, Lakdawalla D, Philipson TJ, et al. Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA. Health Econ. 2010;19(10):1109–1116.
   PubMed Web of Science ®Google Scholar
• Eger S, Mahlich J. Pharmaceutical regulation in Europe and its impact on corporate R&D. Health Econ Rev. 2014;4:23.
   PubMedGoogle Scholar
• Iizuka T, Kubo K. The generic drug market in Japan: will it finally take off? Health Econ Policy Law. 2011;6(3):369–389.
   PubMed Web of Science ®Google Scholar
• Kanavos P, Vandoros S. Determinants of branded prescription medicine prices in OECD countries. Health Econ Policy Law. 2011;6(3):337–367.
   PubMed Web of Science ®Google Scholar